SecBot SecBot
SECBOTREPLAY Home › Report › ACAD

ACAD · Acadia Pharmaceuticals reported strong fourth quarter and full year…

ACADIA PHARMACEUTICALS INC · 8-K filed Feb 25, 2026 at 16:20 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 25, 2026 at 16:20 ET

Acadia Pharmaceuticals reported strong fourth quarter and full year 2025 results, with GAAP revenue growth of 9% and 12% respectively, and non-GAAP adjusted revenue growth of 16% and 14%. The company raised full year 2026 revenue guidance to $1.22–1.28 billion, driven by continued momentum in NUPLAZID and DAYBUE sales, while also announcing a strategic sales force expansion and upcoming catalysts in its R&D pipeline.

  • Q4 2025 GAAP total revenue: $284 million (9% YoY growth); full year 2025 GAAP revenue: $1.07 billion (12% YoY growth)
  • Q4 2025 non-GAAP adjusted revenue: $298 million (16% YoY growth); full year 2025: $1.08 billion (14% YoY growth)
  • NUPLAZID GAAP net sales: $174 million in Q4 2025; non-GAAP adjusted: $189 million (17% YoY growth)
  • DAYBUE GAAP net sales: $110 million in Q4 2025 (13% YoY growth)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access